Abstract

Throughout the past decades, the search for a treatment for severe hemoglobinopathies has gained increased interest within the scientific community. The discovery that ɤ-globin expression from intact HBG alleles complements defective HBB alleles underlying β-thalassemia and sickle cell disease, has provided a promising opening for research directed at relieving ɤ-globin repression mechanisms and, thereby, improve clinical outcomes for patients. Various gene editing strategies aim to reverse the fetal-to-adult hemoglobin switch to up-regulate ɤ-globin expression through disabling either HBG repressor genes or repressor binding sites in the HBG promoter regions. In addition to these HBB mutation-independent strategies involving fetal hemoglobin (HbF) synthesis de-repression, the expanding genome editing toolkit is providing increased accuracy to HBB mutation-specific strategies encompassing adult hemoglobin (HbA) restoration for a personalized treatment of hemoglobinopathies. Moreover, besides genome editing, more conventional gene addition strategies continue under investigation to restore HbA expression. Together, this research makes hemoglobinopathies a fertile ground for testing various innovative genetic therapies with high translational potential. Indeed, the progressive understanding of the molecular clockwork underlying the hemoglobin switch together with the ongoing optimization of genome editing tools heightens the prospect for the development of effective and safe treatments for hemoglobinopathies. In this context, clinical genetics plays an equally crucial role by shedding light on the complexity of the disease and the role of ameliorating genetic modifiers. Here, we cover the most recent insights on the molecular mechanisms underlying hemoglobin biology and hemoglobinopathies while providing an overview of state-of-the-art gene editing platforms. Additionally, current genetic therapies under development, are equally discussed.

Highlights

  • Hemoglobinopathies are the world’s most common group of monogenic disorders with an estimated 7% of the global population carrying these diseases (Piel, 2016)

  • Gene therapy technologies based on lentiviral vector (LV)-mediated HBB gene supplementation have reached advanced clinical trial stages (Table 1)

  • Improved LV designs present reduced safety concerns associated with insertional oncogenesis (e.g., human immunodeficiency virus type 1 (HIV-1) SIN constructs with miniaturized HBB enhancer/promoter elements), life-long monitoring for the emergence of potentially hazardous monoclonal expansions of hematopoietic stem cells (HSCs) progenies, is warranted

Read more

Summary

A Small Key for a Heavy Door

Various gene editing strategies aim to reverse the fetal-to-adult hemoglobin switch to up-regulate È-globin expression through disabling either HBG repressor genes or repressor binding sites in the HBG promoter regions In addition to these HBB mutation-independent strategies involving fetal hemoglobin (HbF) synthesis de-repression, the expanding genome editing toolkit is providing increased accuracy to HBB mutation-specific strategies encompassing adult hemoglobin (HbA) restoration for a personalized treatment of hemoglobinopathies. The progressive understanding of the molecular clockwork underlying the hemoglobin switch together with the ongoing optimization of genome editing tools heightens the prospect for the development of effective and safe treatments for hemoglobinopathies In this context, clinical genetics plays an crucial role by shedding light on the complexity of the disease and the role of ameliorating genetic modifiers.

INTRODUCTION
Results
CONCLUSIONS AND PROSPECTS
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call